These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12728743)

  • 1. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study.
    Chengappa KN; Parepally H; Brar JS; Mullen J; Shilling A; Goldstein JM
    Can J Psychiatry; 2003 Apr; 48(3):187-94. PubMed ID: 12728743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
    Byerly MJ; Nakonezny PA; Rush AJ
    Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies.
    Meulien D; Huizar K; Brecher M
    Hum Psychopharmacol; 2010 Mar; 25(2):103-15. PubMed ID: 20196185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
    Glick ID; Marder SR
    J Clin Psychiatry; 2005 May; 66(5):638-41. PubMed ID: 15889952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
    Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
    Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
    Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder.
    Honer WG; MacEwan GW; Gendron A; Stip E; Labelle A; Williams R; Eriksson H;
    J Clin Psychiatry; 2012 Jan; 73(1):13-20. PubMed ID: 21733490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
    Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study.
    Kahn RS; Schulz SC; Palazov VD; Reyes EB; Brecher M; Svensson O; Andersson HM; Meulien D;
    J Clin Psychiatry; 2007 Jun; 68(6):832-42. PubMed ID: 17592906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.
    McConville BJ; Arvanitis LA; Thyrum PT; Yeh C; Wilkinson LA; Chaney RO; Foster KD; Sorter MT; Friedman LM; Brown KL; Heubi JE
    J Clin Psychiatry; 2000 Apr; 61(4):252-60. PubMed ID: 10830145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
    Emsley R; Turner HJ; Schronen J; Botha K; Smit R; Oosthuizen PP
    J Clin Psychiatry; 2004 May; 65(5):696-701. PubMed ID: 15163258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
    Perkins DO; Gu H; Weiden PJ; McEvoy JP; Hamer RM; Lieberman JA;
    J Clin Psychiatry; 2008 Jan; 69(1):106-13. PubMed ID: 18312044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia.
    Möller HJ; Johnson S; Mateva T; Brecher M; Svensson O; Miller F; Meulien D;
    Int Clin Psychopharmacol; 2008 Mar; 23(2):95-105. PubMed ID: 18301124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia.
    King DJ; Link CG; Kowalcyk B
    Psychopharmacology (Berl); 1998 May; 137(2):139-46. PubMed ID: 9630000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder.
    Lindenmayer JP; Citrome L; Khan A; Kaushik S; Kaushik S
    J Clin Psychopharmacol; 2011 Apr; 31(2):160-8. PubMed ID: 21346616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Administration of once-daily extended release quetiapine in schizophrenic disorders].
    Bartkó G
    Neuropsychopharmacol Hung; 2007 Dec; 9(4):189-95. PubMed ID: 18510263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
    Potkin SG; Thyrum PT; Alva G; Bera R; Yeh C; Arvanitis LA
    J Clin Psychopharmacol; 2002 Apr; 22(2):121-30. PubMed ID: 11910256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
    Potkin SG; Gharabawi GM; Greenspan AJ; Mahmoud R; Kosik-Gonzalez C; Rupnow MF; Bossie CA; Davidson M; Burtea V; Zhu Y; Trivedi JK
    Schizophr Res; 2006 Jul; 85(1-3):254-65. PubMed ID: 16797162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
    Figueroa C; Brecher M; Hamer-Maansson JE; Winter H
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):199-204. PubMed ID: 18948162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.